Belimumab in early systemic lupus erythematosus: A propensity score matching analysis
In SLE patients with a disease duration of less than 6 months, belimumab treatment can promote LLDAS achievement and reduce glucocorticoid dose, leading to a better prognosis. Introducing belimumab in the early stage of SLE may be a beneficial decision.
Authors
- Xiaomei Leng (ORCID: https://orcid.org/0000-0002-0215-9176)
- Xiaofeng Zeng (ORCID: https://orcid.org/0000-0003-1751-4158)
- Chaofan Lu (ORCID: https://orcid.org/0000-0003-1401-7455)
- Lei Dou (ORCID: https://orcid.org/0000-0002-3521-4928)
- Nan He (ORCID: https://orcid.org/0009-0000-7898-8360)
- Hong-Xia Yu
- Mengtao Li
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
- Sir Run Run Shaw Hospital (CN)
- Wuhu Fourth People Hospital (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Immunity Inflammation and Disease
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1002/iid3.1362
- Citations
- 4
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 1.88